Fracture risk associated with use of nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, and acetaminophen and the effects of rheumatoid arthritis and osteoarthritis

Calcified Tissue International

Volumn 79, Issue 2, 2006, Pages 84-94

  Vestergaard, P ^a   Rejnmark, L ^a   Mosekilde, L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Acetaminophen; Fracture; Nonsteroidal anti inflammatory drug; Osteoarthritis; Rheumatoid arthritis; Risk

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; CELECOXIB; CODEINE; CORTICOSTEROID; DICLOFENAC; DIFLUNISAL; ETODOLAC; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; LORNOXICAM; MELOXICAM; MORPHINE; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENYLBUTAZONE; PIROXICAM; ROFECOXIB; SULINDAC; TENOXICAM; TIAPROFENIC ACID; TOLFENAMIC ACID; TRAMADOL; UNINDEXED DRUG;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DENMARK; DOSE RESPONSE; DRUG EFFECT; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZATION; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE;

ACETAMINOPHEN; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; ASPIRIN; FEMALE; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; OSTEOARTHRITIS; REGISTRIES; RISK;

EID: 33748102613     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-006-0020-8     Document Type: Article

References (37)

1. Raisz LG (2001) Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease. Am J Med 110(suppl 3A):43S-45S
2. Raisz LG (1999) Prostaglandins and bone: physiology and pathophysiology. Osteoarthritis Cartilage 7:419-421
3. Raisz LG (1995) Physiologic and pathologic roles of prostaglandins and other eicosanoids in bone metabolism. J Nutr 125:2024S-2027S
4. Kawaguchi H, Pilbeam CC, Harrison JR, et al. (1995) The role of prostaglandins in the regulation of bone metabolism. Clin Orthop Relat Res 313:36-46
5. Warner TD, Guiliano F, Vojnovic I, et al. (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96:7563-7568
6. Carbone LD, Tylavsky FA, Cauley JA, et al. (2003) Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res 18:1795-1802
7. Bauer DC, Orwoll ES, Fox KM, et al. (1996) Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11:29-35
8. Morton DJ, Barrett-Connor EL, Schneider DL (1998) Nonsteroidal anti-inflammatory drugs and bone mineral density in older women: the Rancho Bernardo study. J Bone Miner Res 13:1924-1931
9. van Staa TP, Leufkens HG, Cooper C (2000) Use of nonsteroidal anti-inflammatory drugs and risk of fractures. Bone 27:563-568
10. Beck A, Krischak G, Sorg T, et al. (2003) Influence of diclofenac (group of nonsteroidal anti-inflammatory drugs) on fracture healing. Arch Orthop Trauma Surg 123:327-332
11. Cooper C, Coupland C, Mitchell M (1995) Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 54:49-52
12. Cortet B, Flipo RM, Duquesnoy B, et al. (1995) Bone tissue in rheumatoid arthritis (1). Bone mineral density and fracture risk. Rev Rhum Engl Ed 62:197-204
13. Lane NE, Pressman AR, Star VL, et al. (1995) Rheumatoid arthritis and bone mineral density in elderly women. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 10:257-263
14. Belmonte-Serrano MA, Bloch DA, Lane NE, et al. (1993) The relationship between spinal and peripheral osteoarthritis and bone density measurements. J Rheumatol 20:1005-1013
15. Frank L (2000) Epidemiology. When an entire country is a cohort. Science 287:2398-2399
16. Andersen TF, Madsen M, Jørgensen J, et al. (1999) The Danish National Hospital Register. Dan Med Bull 46:263-268
17. Vestergaard P, Mosekilde L (2002) Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nation-wide follow-up study in 16,416 patients in Denmark. Am J Epidemiol 156:1-10
18. Wacholder S, McLaughlin JK, Silverman DT, et al. (1992) Selection of controls in case-control studies. I. Principles. Am J Epidemiol 135:1019-1028
19. Capella D (1993) Descriptive tools and analysis. In: Dukes MNG (ed) Drug Utilization Studies: Methods and Uses. WHO Regional Publications, European Series 45, Copenhagen, pp 55-78
20. Nielsen GL, Sørensen HT, Zhou W, et al. (1997) The pharmaco-epidemiologic prescription database of North Jutland. Int J Risk Saf Med 10:203-205
21. Charlson ME, Pompei P, Ales KL, et al. (1987) A method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373-383
22. de Groot V, Beckerman H, Lankhorst GJ, et al. (2003) How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 56:221-229
23. Munk-Jørgensen P, Mortensen PB (1997) The Danish Psychiatric Central Register. Dan Med Bull 44:82-84
24. Miettinen OS (1985) Theoretical Epidemiology: Principles of Occurrence Research in Medicine. John Wiley & Sons, New York
25. Vestergaard P, Mollerup CL, Frøkjær VG, et al. (2000) Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 321:598-602
26. Shearn MA (1987) Nonsteroidal anti-inflammatory agents; nonopiate analgesics; drugs used in gout. In: Katzung BG (ed) Basic and Clinical Pharmacology. Appleton & Lange, Norwalk, pp 396-413
27. Aisen PS, Schafer KA, Grundman M, et al. (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289:2819-2826
28. Silberstein S, Tepper S, Brandes J, et al. (2004) Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 62:1552-1557
29. Lovell SJ, Taira T, Rodriguez E, et al. (2004) Comparison of valdecoxib and an oxycodone-acetaminophen combination for acute musculoskeletal pain in the emergency department: a randomized controlled trial. Acad Emerg Med 11:1278-1282
30. Boyle M, Hundy S, Torda TA (1997) Paracetamol administration is associated with hypotension in the critically ill. Aust Crit Care 10:120-122
31. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259
32. Biering Sorensen F, Bohr HH, Schaadt OP (1990) Longitudinal study of bone mineral content in the lumbar spine, the forearm and the lower extremities after spinal cord injury. Eur J Clin Invest 20:330-335
33. Cauley JA, Fullman RL, Stone KL, et al. (2005) Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporosis Int 16:1525-1537
34. Schneider DL, Barrett-Connor E, Morton DJ, et al. (2002) Bone mineral density and clinical hand osteoarthritis in elderly men and women: the Rancho Bernardo study. J Rheumatol 29:1467-1472
35. Hall GM, Spector TD, Griffin AJ, et al. (1993) The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum 36:1510-1516
36. Kroger H, Honkanen R, Saarikoski S, et al. (1994) Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis - a population based study. Ann Rheum Dis 53:18-23
37. Hoidrup S, Grønbæk M, Gottschau A, et al. (1999) Alcohol intake, beverage preference, and risk of hip fracture in men and women. Am J Epidemiol 149:993-1001